Traws Pharma reports positive Phase 2 COVID trial update

Traws Pharma, Inc. filed a current report describing that it issued a press release announcing positive interim data from its Phase 2 study of ratutrelvir, a ritonavir-free treatment, in newly diagnosed COVID subjects.

Rhea-AI Filing Summary

Traws Pharma, Inc. filed a current report describing that it issued a press release announcing positive interim data from its Phase 2 study of ratutrelvir, a ritonavir-free treatment, in newly diagnosed COVID subjects. The filing emphasizes that these results are preliminary and accompanied by customary forward-looking statements language, highlighting that actual outcomes may differ due to various risks and uncertainties. The press release with additional details is included as an exhibit.

Insights

Biotech and clinical-trial analyst

Traws Pharma reports positive interim Phase 2 COVID data but only high-level details are included.

The disclosure focuses on positive interim data from a Phase 2 study of ratutrelvir, described as a ritonavir-free treatment for newly diagnosed COVID subjects. Phase 2 studies typically assess efficacy and dosing in a limited patient group, so encouraging interim results can be important for an early-stage program, even if they are not yet definitive.

The text does not include specific efficacy, safety, or enrollment numbers, and instead directs readers to a press release filed as an exhibit. Extensive forward-looking statement language underlines that future results could differ from current expectations, and that risks described in other SEC documents may affect outcomes. Subsequent company communications or filings would be needed to understand the full clinical profile and next development steps.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Traws Pharma (TRAW) disclose in this current report?

Traws Pharma disclosed that it issued a press release with positive interim data from its Phase 2 study of ratutrelvir in newly diagnosed COVID subjects.

What is the focus of Traws Pharmas Phase 2 study mentioned for TRAW?

The Phase 2 study evaluates ratutrelvir, described as a ritonavir-free treatment, in newly diagnosed COVID subjects.

Where can investors find more details about Traws Pharmas positive interim data?

More details are contained in the press release filed as Exhibit 99.1, which is incorporated by reference into the current report.

Does Traws Pharma (TRAW) include any cautionary language with this COVID study update?

Yes. The company includes extensive forward-looking statements language, noting that actual results may differ due to various risks and uncertainties.

What type of SEC filing did Traws Pharma (TRAW) use for this disclosure?

Traws Pharma used a current report under Item 8.01 Other Events to disclose the press release about its Phase 2 COVID study.

Who signed the Traws Pharma (TRAW) current report?

The report was signed on behalf of Traws Pharma by Iain Dukes, Chief Executive Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/17/2025 - 06:00 AM Learn about SEC filing dates

false 0001130598 0001130598 2025-12-17 2025-12-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): December 17, 2025

Traws Pharma, Inc.

(Exact name of Registrant as specified in its charter)

Delaware		001-36020		22-3627252
(State or Other Jurisdiction of Incorporation or Organization)		(Commission File Number)		(I.R.S. Employer Identification No.)

12 Penns Trail

Newtown, PA 18940

(267) 759-3680

(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive
Offices)

Not Applicable 

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value $.01 per share	TRAW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01 Other Events.

On December 17, 2025, Traws Pharma, Inc. (the “Company”) issued a press release (the “Press Release”) announcing positive interim data for its Phase 2 study to evaluate ratutrelvir, a ritonavir-free treatment, in newly diagnosed COVID subjects. A copy of the Press Release is filed as Exhibit 99.1 to this Current Report on Form 8-K (this “Current Report”) and is incorporated by reference into this Item 8.01.

Forward-Looking Statements

This Current Report, including Exhibit 99.1, contains certain forward-looking statements that involve substantial risks and uncertainties. When used herein, the terms “anticipates,” “expects,” “estimates,” “believes,” “will” and similar expressions, as they relate to the Company or its management, are intended to identify such forward-looking statements.

Forward-looking statements in this Current Report, including Exhibit 99.1, or hereafter, including in other publicly available documents filed with the Securities and Exchange Commission, reports to the stockholders of the Company and other publicly available statements issued or released by the Company involve known and unknown risks, uncertainties and other factors which could cause the Company’s actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. Such future results are based upon management’s best estimates based upon current conditions and the most recent results of operations. These risks include, but are not limited to, the risks set forth herein and in such other documents filed with the Securities and Exchange Commission, each of which could adversely affect the Company’s business and the accuracy of the forward-looking statements contained herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release, dated December 17, 2025.
104		Cover Page Interactive Data File (embedded within the inline XBRL Document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 17, 2025	TRAWS PHARMA, INC.
	By:	/s/ Iain Dukes
		Iain Dukes
		Chief Executive Officer